Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease

被引：22
|
作者：
Ibrahim, Basma M. [1 ]
Tsifansky, Michael D. [2 ,3 ]
Yang, Yan [4 ]
Yeo, Yoon [1 ,5 ]
机构：
[1] Purdue Univ, Coll Pharm, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA
[2] Lutheran Gen Childrens Hosp, Dept Pediat, Div Pediat Crit Care Med, Park Ridge, IL 60068 USA
[3] Lutheran Gen Childrens Hosp, Dept Pediat, Div Pediat Pulmonol, Park Ridge, IL 60068 USA
[4] Jilin Univ, Coll Life Sci, Res Ctr Drug Metab, Changchun 130021, Peoples R China
[5] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA
来源：
EXPERT OPINION ON DRUG DELIVERY | 2011年 / 8卷 / 04期
关键词：
TRANSMEMBRANE CONDUCTANCE REGULATOR; DRY POWDER INHALATION; LIPOSOME-ENCAPSULATED TOBRAMYCIN; OUTER-MEMBRANE PERMEABILITY; INHALED HYPERTONIC SALINE; MEDIATED GENE-TRANSFER; AIRWAY SURFACE LIQUID; ION-TRANSPORT DEFECT; PSEUDOMONAS-AERUGINOSA; IN-VITRO;
D O I：
10.1517/17425247.2011.561310
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review discusses current and emerging therapeutic agents for CF therapy, selected physiological challenges to effective inhalational medication delivery, and various approaches to overcoming these challenges. The reader will find an integrated view of the known inhalational drug delivery challenges and the rationales for recent investigational inhalational drug formulations. Expert opinion: An ideal drug/gene delivery system to CF airways should overcome the tenacious sputum, which presents physical, chemical and biological barriers to effective transport of therapeutic agents to the targets and various cellular challenges.
引用
收藏
页码：451 / 466
页数：16
相关论文
共 50 条
  • [1] DEVELOPMENT OF INHALABLE DRUG FORMULATIONS FOR IDIOPATHIC PULMONARY FIBROSIS
    Vartiainen, Ville
    Raula, Janne
    Koli, Katri
    Myllarniemi, Marjukka
    [J]. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2017, 30 (04) : A19 - A20
  • [2] Inhalable Drug Formulations For Idiopathic Pulmonary Fibrosis
    Vartiainen, V.
    Raula, J.
    Koli, K.
    Kauppinen, E.
    Myllarniemi, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [3] Advances in the Cystic Fibrosis Drug Development Pipeline
    Esposito, Christine
    Kamper, Martin
    Trentacoste, Jessica
    Galvin, Susan
    Pfister, Halie
    Wang, Janice
    [J]. LIFE-BASEL, 2023, 13 (09):
  • [4] Advances in Imaging Cystic Fibrosis Lung Disease
    Walkup, Laura L.
    Woods, Jason C.
    [J]. PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2015, 28 (04) : 220 - 229
  • [5] Advances in gene therapy for cystic fibrosis lung disease
    Yan, Ziying
    McCray, Paul B., Jr.
    Engelhardt, John F.
    [J]. HUMAN MOLECULAR GENETICS, 2019, 28 (R1) : R88 - R94
  • [6] Progress and challenges in fungal lung disease in cystic fibrosis
    Hong, Gina
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (06) : 584 - 590
  • [7] The Development of Lung Disease in Cystic Fibrosis Pigs
    Wine, Jeffrey J.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (29)
  • [8] Challenges facing microRNA therapeutics for cystic fibrosis lung disease
    De Santi, Chiara
    Greene, Catherine M.
    [J]. EPIGENOMICS, 2020, 12 (03) : 179 - 181
  • [9] Challenges in pulmonary fibrosis. 3: Cystic lung disease
    Cosgrove, Gregory P.
    Frankel, Stephen K.
    Brown, Kevin K.
    [J]. THORAX, 2007, 62 (09) : 820 - 829
  • [10] THE DEVELOPMENT AND ROLE OF AUTOIMMUNITY IN CYSTIC FIBROSIS LUNG DISEASE
    Skopelja, S.
    Hamilton, J.
    Jones, J.
    Ashare, A.
    Gifford, A. H.
    Rigby, W.
    [J]. PEDIATRIC PULMONOLOGY, 2016, 51 : 302 - 303
12345